Changeflow GovPing Drug Safety Class 3 Medicines Recall: Bayer Plc, Various Pr...
Urgent Notice Removed Final

Class 3 Medicines Recall: Bayer Plc, Various Products

Favicon for www.gov.uk MHRA Drug & Device Alerts
Published March 12th, 2026
Detected March 13th, 2026
Email

Summary

Bayer Plc is recalling specific batches of Gastrografin, Urografin 150 Solution, and Urografin 150 Injection due to an impurity exceeding acceptable limits. This recall is a precautionary measure at the pharmacy and wholesaler level.

What changed

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 3 Medicines Recall for various products manufactured by Bayer Plc, including Gastrografin gastroenteral solution and Urografin 150 Infusion/Injection. The recall is a precautionary measure because an impurity has been identified above the acceptable limit. Affected products are being recalled at the pharmacy and wholesaler level, with specific batch numbers and expiry dates listed in the notification.

Healthcare providers and pharmacies must immediately stop supplying the affected batches and return them to the supplier. While this is a Class 3 recall, indicating a lower risk, prompt action is necessary to prevent potential patient exposure to the impurity. No specific compliance deadline is mentioned, but the nature of a recall implies immediate cessation of distribution for the specified batches.

What to do next

  1. Cease supply of affected Bayer Plc product batches immediately.
  2. Return recalled stock to the supplier.
  3. Review internal inventory for affected batch numbers.

Source document (simplified)

Class 3 Medicines Recall: Bayer Plc, Various Products, EL(26)A/12

Bayer Plc is recalling all stock of the products listed in this notification as a precautionary measure due to the identification of an impurity above the acceptable limit. The recall is at pharmacy and wholesaler level.

From: Medicines and Healthcare products Regulatory Agency Published 12 March 2026 Message type: Medicines recall/notification Medical specialty: Dispensing GP practices, Pharmacy and Radiology and imaging Issued: 12 March 2026

DMRC reference number

DMRC- 38673150

Marketing Authorisation Holder

Bayer Plc

Medicine Details

Gastrografin gastroenteral solution

PL: 00010/0537

Active ingredients: meglumine amidotrizoate and sodium amidotrizoate

SNOMED code: 9757711000001100

GTIN: 5016703008323

Affected Lot Batch Numbers

| Batch No. | Expiry Date | Pack Size | First Distributed |
| --- | --- | --- | --- |
| MA04HM9 | 02/2028 | 10x100ml | 01/05/2024 |
| MA04JKA | 03/2028 | 10x100ml | 31/05/2024 |
| MA04KFC | 04/2028 | 10x100ml | 30/07/2024 |
| MA04KJ9 | 04/2028 | 10x100ml | 01/08/2024 |
| MA04M60 | 07/2028 | 10x100ml | 23/09/2024 |
| MA04MLL | 08/2028 | 10x100ml | 04/11/2024 |
| MA04MM9 | 09/2028 | 10x100ml | 15/12/2024 |
| MA04MN9 | 09/2028 | 10x100ml | 19/01/2025 |
| MA04NDU | 10/2028 | 10x100ml | 13/02/2025 |
| MA04NNB | 11/2028 | 10x100ml | 06/03/2025 |
| MA04PJL | 12/2028 | 10x100ml | 15/04/2025 |
| MA04PLZ | 12/2028 | 10x100ml | 29/05/2025 |
| MA04PMV | 01/2029 | 10x100ml | 11/07/2025 |
| MA04RL2 | 02/2029 | 10x100ml | 14/08/2025 |
| MA04RL3 | 02/2029 | 10x100ml | 15/09/2025 |
| MA04S6C | 02/2029 | 10x100ml | 30/10/2025 |
| MA04S6B | 02/2029 | 10x100ml | 03/10/2025 |
| MA04S6T | 02/2029 | 10x100ml | 02/12/2025 |
| MA04XJ8 | 07/2029 | 10x100ml | 09/01/2026 |

Medicine Details

Urografin 150 Infusion

PL: 00010/0568

Active ingredients: meglumine amidotrizoate and sodium amidotrizoate

SNOMED code: 8058511000001109 (250 ml 8058911000001102 (500 ml)

GTIN: 5016703000013 (250 ml) 5016703000983 (500 ml)

Affected Lot Batch Numbers

| Batch No. | Expiry Date | Pack Size | First Distributed |
| --- | --- | --- | --- |
| MA044UD | 03/2026 | 1x250ml | 09/02/2023 |
| MA04A58 | 03/2026 | 1x250ml | 27/06/2023 |
| MA04BVD | 07/2026 | 1x250ml | 09/11/2023 |
| MA04BVE | 07/2026 | 1x250ml | 23/01/2024 |
| MA04HS8 | 02/2029 | 1x250ml | 04/06/2024 |
| MA04L2M | 02/2029 | 1x250ml | 18/07/2024 |
| MA04LTC | 05/2029 | 1x250ml | 27/08/2024 |
| MA04NAL | 07/2029 | 1x250ml | 11/12/2024 |
| MA04MK6 | 08/2029 | 1x250ml | 19/11/2024 |
| MA04SJ3 | 09/2029 | 1x250ml | 03/07/2025 |
| MA04NB8 | 10/2029 | 1x250ml | 23/04/2025 |
| MA04UXS | 10/2029 | 1x250ml | 15/10/2025 |
| MA04VPT | 05/2030 | 1x250ml | 12/01/2026 |
| MA042CN | 05/2026 | 1x500ml | 24/06/2022 |
| MA044U4 | 05/2026 | 1x500ml | 01/11/2022 |
| MA048LU | 05/2026 | 1x500ml | 09/03/2023 |
| MA04BV0 | 05/2026 | 1x500ml | 26/07/2023 |
| MA04FRU | 05/2026 | 1x500ml | 12/03/2024 |
| MA044U9 | 07/2026 | 1x500ml | 02/03/2023 |
| MA04TLV | 03/2030 | 1x500ml | 29/07/2025 |

Medicine Details

Urografin 150 Injection

PL: 00010/0569

Active ingredients: meglumine amidotrizoate and sodium amidotrizoate

SNOMED code: 8057711000001100 (10 ml) 8058111000001100 (20 ml)

GTIN: 5016703000860 (10 ml) 5016703000976 (20 ml)

Affected Lot Batch Numbers

| Batch No. | Expiry Date | Pack Size | First Distributed |
| --- | --- | --- | --- |
| MA042JA | 06/2026 | 10x10ml | 28/07/2022 |
| MA046UT | 06/2026 | 10x10ml | 19/12/2022 |
| MA0496X | 06/2026 | 10x10ml | 29/03/2023 |
| MA04AP0 | 06/2026 | 10x10ml | 08/08/2023 |
| MA04BX7 | 06/2026 | 10x10ml | 27/10/2023 |
| MA04FHP | 06/2026 | 10x10ml | 13/06/2024 |
| MA04KJB | 06/2026 | 10x10ml | 15/08/2024 |
| MA04L45 | 06/2026 | 10x10ml | 15/09/2024 |
| MA04S8T | 02/2030 | 10x10ml | 17/06/2025 |
| MA043T7 | 09/2026 | 10x20ml | 13/09/2022 |
| MA046TS | 09/2026 | 10x20ml | 20/02/2023 |
| MA0497C | 09/2026 | 10x20ml | 21/03/2023 |
| MA04R4R | 09/2029 | 10x20ml | 25/04/2025 |

Background

Bayer Plc is recalling all stock of the above products as a precautionary measure due to the identification of an impurity above the acceptable limit. The recall is at pharmacy and wholesaler level.

Advice for Healthcare Professionals:

Stop supplying the above batches immediately. Quarantine all stock and return it to your supplier using your supplier’s approved process.

Advice for Healthcare Professionals to Provide to Patients:

No action is required by patients. The medication is administered by healthcare professionals for use during radiological examinations. The recall is at the wholesaler and pharmacy level.

The products are being recalled out of an abundance of caution, no reports of patient harm have been received from patients relating to this defect.

Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

Additional information:

For all medical information enquiries and information on this product, please email medical.information@bayer.co.uk, or telephone 0118 206 3116.

For stock control enquiries please email orders-uk@bayer.com, or telephone 0118 206 3131.

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully

Defective Medicines Report Centre

10 South Colonnade

Canary Wharf

London

E14 4PU

Telephone +44 (0)20 3080 6574

DMRC@mhra.gov.uk

Download document

Class 3 Medicines Recall: Bayer Plc, Various Products, EL(26)A/12

Updates to this page

Published 12 March 2026 Contents

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
Various
Published
March 12th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Substantive

Who this affects

Applies to
Drug manufacturers Healthcare providers Pharmacy
Geographic scope
National (UK)

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Compliance
Topics
Product Safety Recalls

Get Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when MHRA Drug & Device Alerts publishes new changes.

Free. Unsubscribe anytime.